Patrick Campbell is the managing editor of HCPLive. Formerly the editorial lead of Endocrinology Network, Practical Cardiology, and Rheumatology Network, Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. He now helps to lead coverage in each of these respective areas for HCPLive. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA, and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.
ADA Updates Standards of Care to Include Teplizumab for Delaying T1D, Reflect Emphasis on NAFLD
June 25th 2023At their annual meeting, the American Diabetes Association debuted updates to their Standards of Care to reflect the approval of teplizumab for delaying the onset of type 1 diabetes and underline the importance of screening for NAFLD in type 2 diabetes.
Read More
Study Suggests Bempedoic Acid Could Find Role in Primary Prevention
June 24th 2023An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.
Read More
SURMOUNT-2: Tirzepatide Demonstrates Body Weight-Lowering Effects in T2D
June 24th 2023Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.
Read More
Survodutide, Formerly BI 456906, Impresses in Phase 2 Dose-Finding Trial
June 23rd 2023Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.
Read More
10 Years of Obesity: A Decade of Advancement and Challenges
June 23rd 2023To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.
Read More
Gestational Diabetes Makes Achieving Glycemic Control More Difficult Following Pregnancy
June 21st 2023An analysis of data from the NYC A1C Registry suggests women with gestational diabetes were more likely to develop diabetes after giving birth and were also more likely to have difficulty achieving glycemic control after diagnosis.
Read More
FDA Approves Empagliflozin, Empagliflozin plus Metformin for Pediatric Type 2 Diabetes
June 20th 2023The FDA's historic June 20, 2023 approval of empagliflozin (Jardiance) and empagliflozin plus metformin hydrochloride (Synjardy) marks the first pediatric type 2 diabetes indication for the SGLT2 inhibitor class and comes less than a year after the debut of DINAMO data.
Read More
FDA Approves Colchicine Tablets for Reducing Cardiovascular Risk
June 20th 2023Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.
Read More
FDA Approves Updated Label for Mavacamten in Obstructive Hypertrophic Cardiomyopathy
June 16th 2023On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.
Read More
CLEAR Outcomes Data at ENDO 2023 Provides Further Insight into Effects of Bempedoic Acid
June 15th 2023An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.
Read More
Recognizing the Bidirectional Risk of Menopause and Diabetes, with Erin Michos, MD
June 14th 2023During a presentation at the Metabolic Insitute of America's 7th Heart in Diabetes meeting, Erin Michos, MD, broke down the importance of recognizing the bidirectional risk between diabetes and menopause.
Read More
Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial
June 14th 2023New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.
Read More
Study Links Weight Loss Surgery in Adolescents, Young Adults to Weakened Bones
June 13th 2023A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.
Read More
SGLT2 Inhibitor Prescription Rates Lag Behind in HFrEF, with Stephen Greene, MD
June 13th 2023Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.
Read More
Metformin Could Reduce Long COVID Risk in People with Overweight or Obesity
June 9th 2023Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.
Read More
Heart Attack During COVID Lockdowns Linked to Shorter Life Expectancy
June 8th 2023A decision-analytic model leveraging data from the UK and Spain suggests people who experienced STEMI during COVID-19 lockdown periods could have a reduced life expectancy relative to their counterparts who experienced similar events in prepandemic periods.
Read More
Lack of Timely Follow-up Care After Heart Failure Common in Type 2 Diabetes
June 7th 2023An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.
Read More
Study Captures Patient Perspective When Considering Discontinuation of Gout Therapy
June 6th 2023Data presented at EULAR 2023 details the factors that matter most to patients with gout when considering the continuation or discontinuation of urate-lowering therapy after achieving clinical remission.
Read More
Disease Activity-Guided Dosing Safe, Effective for up to 10 Years in Rheumatoid Arthritis
June 6th 2023Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.
Read More